Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume – Time to Buy?

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares saw an uptick in trading volume on Monday . 198,627 shares traded hands during trading, an increase of 126% from the previous session’s volume of 87,898 shares.The stock last traded at $7.8350 and had previously closed at $8.03.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. UBS Group decreased their price target on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 23rd. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a report on Monday, December 22nd. Wall Street Zen downgraded Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Canaccord Genuity Group upgraded Telix Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 6th. Finally, Royal Bank Of Canada assumed coverage on shares of Telix Pharmaceuticals in a research note on Monday, December 15th. They set a “hold” rating for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Telix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Trading Down 2.7%

The company has a 50-day moving average price of $9.56 and a 200-day moving average price of $11.52.

Institutional Investors Weigh In On Telix Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC acquired a new position in Telix Pharmaceuticals during the 3rd quarter valued at about $1,883,000. Pier Capital LLC bought a new position in shares of Telix Pharmaceuticals in the second quarter valued at approximately $3,037,000. Portland Investment Counsel Inc. acquired a new position in shares of Telix Pharmaceuticals during the third quarter valued at approximately $1,225,000. Lazard Asset Management LLC bought a new stake in Telix Pharmaceuticals during the third quarter worth approximately $1,097,000. Finally, Russell Investments Group Ltd. acquired a new stake in Telix Pharmaceuticals in the second quarter worth approximately $975,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.